Beijing Jiuzhou Jikang Pharmaceutical

Beijing Jiuzhou Jikang Pharmaceutical is a clinical-stage biotechnology company headquartered in Beijing, China, dedicated to the discovery and development of innovative peptide-based therapeutics. The company primarily focuses on metabolic and endocrine disorders, with a specific emphasis on obesity, type 2 diabetes, and non-alcoholic steatohepatitis (NASH). Its lead candidate, JJK-002, is a long-acting dual agonist of the glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP) receptors, currently undergoing clinical evaluation. Jiuzhou Jikang leverages its expertise in peptide engineering to create differentiated treatments with improved efficacy and safety profiles. The company has secured significant funding from prominent Chinese venture capital firms to advance its pipeline through clinical milestones. By addressing the unmet needs of patients with chronic metabolic conditions, Jiuzhou Jikang aims to become a leader in the next generation of metabolic medicine.